Avid Bioservices Acquired by GHO and Ampersand Capital
I'm PortAI, I can summarize articles.
Avid Bioservices has been acquired by GHO Capital and Ampersand Capital Partners for approximately $1.1 billion, leading to its delisting from Nasdaq. This acquisition aims to support Avid's growth and enhance its capabilities in the CDMO sector. Avid Bioservices specializes in the development and manufacturing of biologics, offering a range of services for the biotechnology and biopharmaceutical industries. The merger is expected to accelerate innovation and expand Avid's global market reach, benefiting stakeholders.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments